Navigation Links
Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms
Date:3/23/2009

CINCINNATI March 23, 2009 A review by researchers at Northwestern University (Chicago, IL.) and University of Michigan (Ann Arbor, MI) of the utility of probiotics in the treatment of Irritable Bowel Syndrome (IBS) found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty. Bifidobacterium infantis 35624 is marketed as Bifantis® and can be found in a daily probiotic supplement by Procter & Gamble. The researchers reviewed 16 random-controlled-studies, evaluating the efficacy, safety and tolerability of probiotics in the treatment of IBS. With the exception of the Bifidobacterium infantis 35624 studies, researchers found the other trials did not use an appropriate study design and did not adequately report adverse events. The article was published on the American Journal of Gastroenterology website in advance of appearing in the publication's April 2009 issue1.

Irritable Bowel Syndrome affects one in five Americans and treatment options are limited. Darren. M Brenner, Division of Gastroenterology and Department of Internal Medicine, at Northwestern University and lead investigator of this study, hypothesized that alterations in gut microflora may contribute to the development of IBS symptoms, and believed these symptoms could be improved by probiotics. "Probiotics are gaining popularity for the treatment of multiple gastrointestinal disorders, including IBS," said Brenner, MD. "After assessment of the methodological and statistical designs of these studies, B. infantis 35624 was the only probiotic that showed repeated efficacy."

Clinical evidence and support for Bifantis continues to grow

Bifidobacterium infantis 35624, discovered in the early 1990s by microbiologists at Alimentary Health in Cork, Ireland in partnership with P&G, has been independently tested and evaluated in several clinical trials conducted with humans. This latest review provides continued clinical evidence of Bifantis efficacy in helping to manage a range of gastrointestinal issues including abdominal pain, bloating, constipation, diarrhea, gas and urgency. Bifantis efficacy data has been published or referenced in several medical journals, including the American Journal of Gastroenterology2 , Gastroenterology3 , New England Journal of Medicine4 , Public Library of Science (PLoS)5 and Nutrition in Clinical Practice6. Bifantis is found in the number one gastroenterologist recommended probiotic supplement in the United States7 .

Susan Abeln, Principal Scientist at Procter & Gamble said, "P&G has worked with Alimentary Health to study and develop a supplement with Bifantis because we firmly believe in the benefits of this strain for the millions of Americans struggling to manage digestive upsets each day. We're excited to make Bifantis available to consumers nationwide this spring."

Further credentialing the probiotic strain, P&G recently announced that Bifantis meets the probiotic guidelines established by The International Scientific Association for Probiotics and Prebiotics (ISAPP). These guidelines include five key criteria that consumers should consider when selecting a probiotic product - strain specificity, clinical proof, packaging, and the quality and quantity of probiotics in a product. Bifantis is proven to fully meet these guidelines, making it a good option for those who want to build and maintain a natural defense against abdominal discomfort and episodic digestive upsets such as constipation, diarrhea, urgency, gas and bloating.


'/>"/>

Contact: Chido Tsemunhu
Chido.Tsemunhu@mslworldwide.com
212-468-3681
Manning Selvage & Lee
Source:Eurekalert

Related biology news :

1. Stanford researchers publish review of US medical device regulation
2. Medicines derived from cannabis: a review of adverse events
3. Review article provides tools for the Rosaceae genomics community
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Experts discuss applying systematic review to the field of nutrition
6. Biophysical Reviews makes debut in 2009
7. A re-review of peer review: Leading journal looks to end the review nightmare
8. Swedish university honors probiotics scientist
9. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
10. Vitamin E trials fatally flawed
11. Research team says extraterrestrial impact to blame for Ice Age extinctions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... The AMA is happy to announce that $48,000 ... the nation. The scholarships are created through funds donated by model aviation organizations and ... set by the AMA Scholarship Committee, which is made up of model aviation pilots ...
(Date:4/21/2017)... ... 21, 2017 , ... Frederick Innovative Technology Center, Inc. (FITCI), ... businesses, recently earned a $77,518 grant from the Rural Maryland Council (RMC) to ... is Frederick’s first incubator. A non-profit corporation, FITCI is a public-private partnership of ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... announced their strategic partnership to offer a full spectrum of digital security goods ... suite of biometric products and the ground-breaking proactive cybersecurity services and products through ...
(Date:4/20/2017)... ... 20, 2017 , ... USDM Life Sciences , the leading risk management, ... is pleased to announce Holger Braemer as Vice President of its Europe ... in Germany. , Braemer is an integral part of USDM’s expansion of services ...
Breaking Biology Technology: